Immunofluorescence analysis of MDM2 in subconfluent U2OS cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 3% BSA for 15 minutes at room temperature. The cells were probed with a MDM2 Mouse Monoclonal Antibody (33-7100) at 1.5 µg/mL for 1 hour at room temperature and then labeled with a Goat anti-Mouse IgG (H+L) Superclonal Secondary Antibody, Alexa Fluor 488 conjugate (Product # A28175) at a dilution of 1:400 for 30 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with Hoechst Dye. F-actin (Panel c: red) was stained with DyLight 554 Phalloidin (Product # 21834). Panel d is a merged image showing predominantly nuclear localization. Panel e shows no primary antibody control. The images were captured at 20X magnification.
|Tested species reactivity||Human|
|Published species reactivity||Rat, Bacteria, Human, Not Applicable, Guinea pig|
|Host / Isotype||Mouse / IgG2b, kappa|
|Immunogen||Synthetic peptide derived from the n-terminal region of human MDM2|
|Storage buffer||PBS, pH 7.4, with 1mg/ml BSA, 30% glycerol|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||1-2 ug/ml|
|Immunofluorescence (IF)||1-2 ug/ml|
|Immunohistochemistry (IHC)||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||2-3 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (Paraffin) (IHC (P))||See 3 publications below|
|Western Blot (WB)||See 1 publications below|
|Immunohistochemistry (Paraffin, Frozen) (IHC (P, F))||See 4 publications below|
|Immunohistochemistry (IHC)||See 4 publications below|
|Miscellaneous PubMed (MISC)||See 3 publications below|
This antibody recognizes the ~90 kDa (apparent MW) MDM2 protein. Also recognizes isoforms at ~57 and ~74/76 kDa.
MDM2 is a target of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of MDM2 can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report.
33-7100 was used in immunohistochemistry - paraffin section to characterize a primary myxoid liposarcoma with chondroid and osseous components
|Weingertner N,Neuville A,Chibon F,Ray-Coquard I,Marcellin L,Ghnassia JP||Applied immunohistochemistry and molecular morphology : AIMM (23:230)||2015|
alpha-fetoprotein expression in a dedifferentiated liposarcoma.
33-7100 was used in immunohistochemistry - paraffin section to present a unique case of relapsing retroperitoneal dedifferentiated liposarcoma with alpha-fetoprotein ectopic production
|Bosco M,Allia E,Coindre JM,Odasso C,Pagani A,Pacchioni D||Virchows Archiv : an international journal of pathology (448:517)||2006|
Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location.
33-7100 was used in immunohistochemistry - paraffin section to present the case of a patient with a rare atypical lipomatous tumor with spindle cell features
|Mentzel T,Toennissen J,Rütten A,Schaller J||Virchows Archiv : an international journal of pathology (446:300)||2005|
Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/ß-catenin signaling.
33-7100 was used in western blot to report proof-of-principle studies targeting CDH7 for treating gastric cancer.
|Qiu HB,Zhang LY,Ren C,Zeng ZL,Wu WJ,Luo HY,Zhou ZW,Xu RH||PloS one (8:null)||2013|
|Human||Not Cited||MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.||Yoshida A,Ushiku T,Motoi T,Beppu Y,Fukayama M,Tsuda H,Shibata T||The American journal of surgical pathology (36:423)||2012|
|Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.||Weaver J,Goldblum JR,Turner S,Tubbs RR,Wang WL,Lazar AJ,Rubin BP||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (22:66)||2009|
|Human||Not Cited||Reproducibility of MDM2 and CDK4 staining in soft tissue tumors.||Binh MB,Garau XS,Guillou L,Aurias A,Coindre JM||American journal of clinical pathology (125:693)||2006|
|Human||Not Cited||MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.||Khor LY,Desilvio M,Al-Saleem T,Hammond ME,Grignon DJ,Sause W,Pilepich M,Okunieff P,Sandler H,Pollack A||Cancer (104:962)||2005|
MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
33-7100 was used in immunohistochemistry to examine expression of MDM2-CDK4 in low-grade osteosarcomas and fibrous or fibro-osseous lesions of the bone or paraosseous soft tissue.
|Dujardin F,Binh MB,Bouvier C,Gomez-Brouchet A,Larousserie F,Muret Ad,Louis-Brennetot C,Aurias A,Coindre JM,Guillou L,Pedeutour F,Duval H,Collin C,de Pinieux G||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (24:624)||2011|
|Not Applicable||Not Cited||
Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma.
33-7100 was used in immunohistochemistry to discuss a rare presentation of a lipoleiomyosarcoma and review the method of pathologic diagnosis
|Nahal A,Meterissian S||American journal of clinical oncology (32:353)||2009|
|Not Applicable||Not Cited||
Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion.
33-7100 was used in immunohistochemistry to discuss the properties of desmoid tumors
|Amiot A,Dokmak S,Sauvanet A,Vilgrain V,Bringuier PP,Scoazec JY,Sastre X,Ruszniewski P,Bedossa P,Couvelard A||JOP : Journal of the pancreas (9:339)||2008|
|Human||1:100||Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.||Wang YC,Lin RK,Tan YH,Chen JT,Chen CY,Wang YC||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (23:154)||2005|
Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant.
33-7100 was used in immunohistochemistry - paraffin section to use 9 cases of well-differentiated/dedifferentiated liposarcoma to characterize unappreciated features
|Yoshida A,Ushiku T,Motoi T,Shibata T,Fukayama M,Tsuda H||The American journal of surgical pathology (34:1361)||2010|
Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.
33-7100 was used in immunohistochemistry (frozen) to characterize dedifferentiated liposarcomas with an inflammatory malignant fibrous histiocytoma component.
|Coindre JM,Hostein I,Maire G,Derré J,Guillou L,Leroux A,Ghnassia JP,Collin F,Pedeutour F,Aurias A||The Journal of pathology (203:822)||2004|
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.
33-7100 was used in immunohistochemistry (paraffin) to report that most so-called malignant fibrous histiocytomas from the retroperitoneum are dedifferentiated liposarcoma.
|Coindre JM,Mariani O,Chibon F,Mairal A,De Saint Aubain Somerhausen N,Favre-Guillevin E,Bui NB,Stoeckle E,Hostein I,Aurias A||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (16:256)||2003|